About Skystar Bio-Pharmaceutical (OTCMKTS:SKBI)
Skystar Bio-Pharmaceutical Co., Ltd. is a manufacturer and distributor of veterinary medicines and healthcare products in China. The Company develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine (TCM); topicals, supplements, probiotics, and diagnostic kits and animal, animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets within China. The Company operates four product lines: Probiotics, Veterinary Medicine, Veterinary Vaccines and Feed Additives. The Company provides a range of veterinary products serving regional micro-farms offering, such as Veterinary vaccines, including aquaculture, Veterinary medicines, Pro-biotic microorganisms and Animal feed additives. The Company's Veterinary drug products include Ivermectin Premix, Feizhu San, Tilmicosin Premix, Stimulated egg powder, Wulingsan, Yimu Shenghua San, Qingwen Baidu San and Spectinomycin Hydrochloride Injection.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Frequently Asked Questions
What is Skystar Bio-Pharmaceutical's stock symbol?
Skystar Bio-Pharmaceutical trades on the OTCMKTS under the ticker symbol "SKBI."
Who are some of Skystar Bio-Pharmaceutical's key competitors?
Some companies that are related to Skystar Bio-Pharmaceutical include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX).
Who are Skystar Bio-Pharmaceutical's key executives?
Skystar Bio-Pharmaceutical's management team includes the folowing people:
- Weibing Lu, Chairman of the Board, Chief Executive Officer (Age 51)
- Bing Mei, Chief Financial Officer (Age 51)
- Wei Wen, Secretary, Director (Age 46)
- R. Scott Cramer, Director (Age 50)
- Mark D. Chen, Independent Director (Age 47)
- Qiang Fan, Independent Director (Age 58)
- Chengtun Qu, Independent Director (Age 48)
- Weirong Shen, Independent Director (Age 48)
Has Skystar Bio-Pharmaceutical been receiving favorable news coverage?
Media headlines about SKBI stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Skystar Bio-Pharmaceutical earned a coverage optimism score of 0.16 on Accern's scale. They also assigned news articles about the healthcare company an impact score of 44.54 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Skystar Bio-Pharmaceutical?
Shares of SKBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Skystar Bio-Pharmaceutical's stock price today?
One share of SKBI stock can currently be purchased for approximately $0.0001.
How can I contact Skystar Bio-Pharmaceutical?
Skystar Bio-Pharmaceutical's mailing address is RM 10601 JIEZUO PLAZA NO. 4 FENGHUI ROAD SOUTH, XIAN F4, . The healthcare company can be reached via phone at 86-29-8819-3188 or via email at [email protected]
MarketBeat Community Rating for Skystar Bio-Pharmaceutical (SKBI)MarketBeat's community ratings are surveys of what our community members think about Skystar Bio-Pharmaceutical and other stocks. Vote "Outperform" if you believe SKBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SKBI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Analyst Ratings History
(Data available from 4/23/2016 forward)
Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Earnings History and Estimates Chart
Skystar Bio-Pharmaceutical (OTCMKTS SKBI) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2014||Q3 2014||$0.57||$18.35 million||View||N/A|
|8/14/2014||Q2 2014||$0.36||$14.24 million||View||N/A|
|5/15/2014||Q413||$0.13||$5.53 million||$6.83 million||View||N/A|
|3/31/2014||Q4 2013||$0.29||$9.63 million||View||N/A|
|11/15/2013||Q313||$0.49||$8.93 million||$15.99 million||View||N/A|
|8/15/2013||Q1 2013||$0.49||$8.90 million||$11.30 million||View||N/A|
|5/16/2013||Q113||$0.09||$7.93 million||$5.53 million||View||N/A|
|11/15/2012||Q312||$0.36||$20.90 million||$8.90 million||View||N/A|
Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Skystar Bio-Pharmaceutical (OTCMKTS SKBI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.80%
Skystar Bio-Pharmaceutical (OTCMKTS SKBI) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/26/2015||John M Gregory||Major Shareholder||Buy||63,900||$2.91||$185,949.00|| |
|5/6/2015||John M Gregory||Major Shareholder||Buy||50,000||$3.47||$173,500.00|| |
|4/16/2015||John M Gregory||Major Shareholder||Buy||35,000||$3.82||$133,700.00|| |
|2/2/2015||John M Gregory||Major Shareholder||Buy||38,730||$4.21||$163,053.30|| |
|12/23/2014||John M Gregory||Major Shareholder||Buy||70,800||$4.28||$303,024.00|| |
|12/10/2014||John M Gregory||Major Shareholder||Buy||103,016||$4.56||$469,752.96|| |
Skystar Bio-Pharmaceutical (OTCMKTS SKBI) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Income Statement, Balance Sheet and Cash Flow Statement
Skystar Bio-Pharmaceutical (OTCMKTS SKBI) Stock Chart for Monday, April, 23, 2018